SIP
IOVA icon

Stoneridge Investment Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Stoneridge Investment Partners’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,993
Closed -$37K – 147
2025
Q3 		$37K Buy
16,993
+631
+4% +$1.49K 0.03% 121
2025
Q2 		$28K Buy
+16,362
New +$40.7K 0.02% 124

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stoneridge Investment Partners's IOVA Position: Q4 2025 in Review

Stoneridge Investment Partners sold out of Iovance Biotherapeutics (IOVA) in Q4 2025, closing a stake of 16,993 shares — an estimated $37K sold.

Stoneridge Investment Partners first reported a position in IOVA in Q2 2025 and held it in 2 quarters. The position peaked at $37K in Q3 2025. 263 funds tracked by Wall St. Rank hold IOVA as of Q4 2025.

  • Stoneridge Investment Partners reported no remaining Iovance Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Stoneridge Investment Partners sold 16,993 Iovance Biotherapeutics shares in Q4 2025, an estimated $37K.
  • Stoneridge Investment Partners first reported a position in Iovance Biotherapeutics in Q2 2025 and held it in 2 quarters.
  • Stoneridge Investment Partners's Iovance Biotherapeutics position peaked at $37K in Q3 2025.
  • 263 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2025.

Based on Stoneridge Investment Partners's 13F filing for Q4 2025, filed 5 Feb 2026.